Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMNOE0V)

Drug Name

2-phenyl-N-(1-phenylethyl)quinoline-4-carboxamide Drug Info

Synonyms

CHEMBL274763; 2-phenyl-N-(1-phenylethyl)quinoline-4-carboxamide; AC1ME6SQ; Oprea1_279909; SCHEMBL4477684; MolPort-001-501-804; IEDWYQQEMKCMSQ-UHFFFAOYSA-N; BDBM50074822; STK047893; AKOS022078440; AKOS003267625; MCULE-5320435270; ST45002516; 2-phenyl-N-(1-phenylethyl)-4-quinolinecarboxamide; (2-phenyl(4-quinolyl))-N-(phenylethyl)carboxamide; 2-Phenyl-quinoline-4-carboxylic acid (1-phenyl-ethyl)amide; 2-Phenyl-quinoline-4-carboxylic acid (1-phenyl-ethyl)-amide

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

Cross-matching ID

PubChem CID: 2849628
TTD Drug ID: DMNOE0V

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Discontinued Drug(s)

Preclinical Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Neuromedin-K receptor (TACR3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fezolinetant	DMHDQZD	Hot flushes	GA30	Approved	[2]
Elinzanetant	DMC6EFI	Hot flushes	GA30	Phase 3	[3]
Senktide	DMOH8LD	Epilepsy	8A60-8A68	Phase 2	[4]
AZD2624	DMZLGQV	Multiple sclerosis	8A40	Phase 2	[5]
Talnetant	DMQKZDT	Schizophrenia	6A20	Phase 2	[6]
GSK1144814	DMK3S9J	Alcohol dependence	6C40.2	Phase 1	[7]
Osanetant	DMMT4PB	Schizoaffective disorder	6A21	Discontinued in Phase 2b	[6]
CS-003	DM1AEVT	Chronic obstructive pulmonary disease	CA22	Discontinued in Phase 2	[8]
SSR-146977	DMR9JA8	Psychotic disorder	6A20-6A25	Discontinued in Phase 1	[9]
SB222200	DM6X0PZ	Schizoaffective disorder	6A21	Preclinical	[10]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Neuromedin-K receptor (TACR3)	TTBPGLU	NK3R_HUMAN	Inhibitor	[1]

------------------------------------------------------------------------------------

References

1	Virtual screening to identify novel antagonists for the G protein-coupled NK3 receptor. J Med Chem. 2010 Nov 25;53(22):8080-8.
2	Fezolinetant for treatment of moderate-to-severe vasomotor symptoms associated with menopause (SKYLIGHT 1): a phase 3 randomised controlled study. Lancet. 2023 Apr 1;401(10382):1091-1102.
3	Elinzanetant (NT-814), a Neurokinin 1,3 Receptor Antagonist, Reduces Estradiol and Progesterone in Healthy Women. J Clin Endocrinol Metab. 2021 Jul 13;106(8):e3221-e3234.
4	Implication of nigral tachykinin NK3 receptors in the maintenance of hypertension in spontaneously hypertensive rats: a pharmacologic and autoradiographic study. Br J Pharmacol. 2003 Feb;138(4):554-63.
5	The selective neurokinin 3 antagonist AZD2624 does not improve symptoms or cognition in schizophrenia: a proof-of-principle study.J Clin Psychopharmacol.2014 Apr;34(2):199-204.
6	Pharmacological characterization of senktide-induced tail whips. Neuropharmacology. 2010 Jan;58(1):259-67.
7	Pharmacokinetics and central nervous system effects of the novel dual NK1 /NK3 receptor antagonist GSK1144814 in alcohol-intoxicated volunteers.Br J Clin Pharmacol.2013 May;75(5):1328-39.
8	Emerging drugs for the treatment of chronic obstructive pulmonary disease. Expert Opin Emerg Drugs. 2006 May;11(2):275-91.
9	Biochemical and pharmacological activities of SSR 146977, a new potent nonpeptide tachykinin NK3 receptor antagonist. Can J Physiol Pharmacol. 2002 May;80(5):482-8.
10	Evidence for mediation of nociception by injection of the NK-3 receptor agonist, senktide, into the dorsal periaqueductal gray of rats. Psychopharmacology (Berl). 2009 May;204(1):13-24.